3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Urinary Bladder Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Cancer
1
Interventions
pembrolizumab
25
Gemcitabine
21
Nivolumab
17
Cisplatin
17
atezolizumab
14
Carboplatin
11
avelumab
9
vinflunine
7
Ipilimumab
7
Paclitaxel
6
Docetaxel
5
enfortumab vedotin
4
cabazitaxel
4
Pemetrexed
4
Mitomycin
4
cabozantinib
3
Taxes
3
Rogaratinib
3
Magnetic Resonance Spectroscopy
3
Injections
3
Albumin-Bound Paclitaxel
3
tremelimumab
2
sacituzumab govitecan
2
pemigatinib
2
niraparib
2
lenvatinib
2
bempegaldesleukin
2
apatorsen
2
XRP6258
2
Vitamin D
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Transitional Cell
×
bempegaldesleukin
×
Clear all
NCT03785925
2023-03-28
PIVOT-10
Nektar Therapeutics
Phase 2
Completed
192 enrolled
16 charts
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts